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Immigrants from low- and medium-income countries have a higher risk of cervical cancer due both to barriers in
access to screening and to higher human papillomavirus (HPV) prevalence.
In the near future many screening programmes in industrialised countries will replace Pap test with HPV as primary
test. In order to plan future interventions, it is essential to understand how the HPV screening performs in immigrant
women.
Methods: We conducted a survey on the main performance indicators from some of the HPV DNA-based pilot
programmes in Italy, comparing regular immigrant women, identified as women resident in Italy who were born
abroad, with women who were born in Italy. All the programmes applied the same protocol, with HPV as stand-alone
test starting for women of 25 or 35 to 64 years of age. Cytology triage is performed for positive women; those ASC-US
or more severe are referred directly to colposcopy; negative women are referred to repeat HPV after one year.
Results: Overall, 162,829 women were invited, of whom 22,814 were born abroad. Participation was higher for
Italy-born than born abroad (52.2% vs. 43.6%), particularly for women over 45 years. HPV positivity rate was higher
in immigrants: 7.8% vs. 6.1%, age-adjusted Relative Risk (age-adj RR) 1.18, 95% confidence interval (95% CI) 1.13-1.22.
The proportion of women with positive cytology triage was similar in the two groups (42%). Cervical Intraepithelial
Neoplasia (CIN) grade 2 or more severe detection rate was higher for born abroad (age-adj RR 1.65, 95% CI 1.45-1.89).
The difference was stronger when considering only CIN3 or more severe (age-adj RR 2.29, 95% CI 1.90-2.75). Both HPV
positivity and CIN2 or more severe detection rate had a different age curve in born abroad compared with Italy-born:
in the former, the risk was almost flat, while in the latter it declined rapidly with age.
Conclusion: Compliance with HPV screening is lower for migrant women, who are affected by higher HPV positivity
and CIN3 cancer detection rates.Introduction
Persistent infection with oncogenic HPV types is the
necessary, but not sufficient, cause of cervical cancer
[1,2]. Wide differences in cervical cancer incidence and
mortality have been observed around the world, with
more than 85% of invasive cancers occurring in low-
and middle-income countries [3]. The differences in* Correspondence: paolo.giorgirossi@ausl.re.it
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Pap test use and screening programmes [4-6].
Several studies have shown that migrant women from
low- and medium- income countries have higher risk of
cervical cancer [7-11] and usually maintain the same
cervical cancer risk as that of their countries of origin
for several years [12-15]. Both of the main determinants
of cervical cancer can be related to the differential risk in
immigrant women: many countries of origin have high
prevalence of HPV infection [16,17]; Pap test coverage in
migrant women is lower than in native women becausel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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very low [17] and because there could be several barriers
to screening access in the host country [5,18-22].
Migration in Italy is a relatively recent phenomenon:
in 1991, foreigners resident in Italy were less than 1% of
the total population while in 2011 they were 7.5%, with
some cities over 16%. Most of immigrant women in Italy
are in the target age of cervical cancer screening [23,24].
Screening with HPV DNA as primary test has been
demonstrated to be more effective in preventing cancer
[25]. Many international guidelines are now introducing
HPV test as primary screening test [26-30].
Screening programmes in Italy cover the vast majority
of the resident population, without any difference with
regard to citizenship [31]. In 2007, the first pilot pro-
gramme using HPV DNA as primary screening test was
implemented [32], followed by several other experiences
in 2009–10 [33-36]. All the screening programmes,
including HPV DNA pilot programmes, systematically
collect information about invitations, test results, col-
poscopy and histology, and participate in a national
survey [37,38]. In 2012, the survey included a focus on
immigrant women.
Objective
In this paper we compare the screening results in 7




In Italy, according to the European Commission recom-
mendations (2003) [39], the Regional Health Systems
are committed to organize screening programmes that
actively invite the target female population. The national
guidelines recommend a Pap test every three years for
women aged 25–64 years. All women resident must be
invited and all screening tests, ascertainments and treat-
ments are free of charge.
Since 2007, after the publication of the results of three
large randomised trials on HPV DNA as primary test
[40-42], some Local Health Authorities started HPV
DNA-based pilot programmes. All the programmes
adopted the same protocol: [43] HPV DNA as primary
test, followed by triage with cytology: HPV positive
(HPV+) and cytology positive (cyto+) prompted imme-
diate colposcopy, while HPV+ cytology negative (cyto-)
prompted one-year follow up with HPV. Some pilot
programmes adopted this strategy for women age 25–
64 years, others for women age 35 to 64 only. The inter-
val for HPV negative (HPV-) women was 3 years for all
women recruited until 2012. Women receive the test
results by letter if negative; they are contacted by phone
in case of positivity (and also by letter, in someprogrammes only if there is no answer; in other pro-
grammes, always) to make an appointment for colposcopy.
In some programmes women who are HPV positive and
cytology negative are contacted only by letter while in
some other programmes they are contacted by phone. In
any case women are actively contacted to communicate
the results of the screening tests.
Some of the projects were randomised pragmatic trials;
the others were intervention studies with historical or
geographical controls. The pilot programmes tested
feasibility, organizational impact, acceptability (for
operators and women), compliance with invitation and
follow-up protocols, performance of cytology triage
and, finally, they collected field information for eco-
nomic and budget impact analysis.
All the projects were approved by the local Ethics
Committees or were established by law by the regional
health authority.
The Osservatorio Nazionale Screening, supported by
the Centro per la Prevenzione Oncologica (CPO),
Piedmont, annually collects aggregated data from all the
Italian screening programmes, whose results are pub-
lished in an annual national report [37,38].
The survey methods were developed by the GISCi
(Gruppo Italiano per lo Screening Cervicale) in 1999
[44], and are consistent with the minimum dataset of
indicators of the European guidelines [45].
From 2012, the survey collected information from the
HPV DNA-based screening.
The migrant survey
In 2012, the GISCi promoted the collection of information
on immigrant women inside the national survey. The coun-
try of birth was used to identify the migrant status. Only
two programmes (Reggio Emilia and Torino) classified the
countries as low- and medium-income or other (i.e., high
income), according to the classification of “high migration
pressure countries” of the Italian Ministry of Health [46].
Data were collected with the same form as the official
survey and were disaggregated by age and migration
status, while they did not distinguish women at first vs.
subsequent screening episodes. Furthermore, we re-
quested data for the three-year period 2009–11.
HPV DNA molecular analyses
HPV test was performed on liquid based cytology samples
or on samples specific to HPV test. In the latter case, a
smear was obtained and fixed before taking the sample for
molecular testing.
All the programmes used Hybrid Capture 2 (Qiagen),
on both liquid based cytology (PreservCyt) or on Standard
Transport Medium (STM). For programmes using two
samples (cytology and STM) the denaturation and
hybridization was directly performed on the sampling
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4 ml of PreservCyt were transferred for the conversion
according to the manufacturer’s instructions. HPV
results were classified as positive or negative for high-
risk types. The types included were 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, and 68.
Cytology
In the programmes using conventional smears, only the
slides of HPV+ women were stained and interpreted. In the
case of liquid based cytology, the slide was prepared from
residual material after HPV testing only when HPV+.
Cytology results were classified according to TBS 2001. All
the programmes referred women with ASC-US or more se-
vere cytology to colposcopy. Women with an unsatisfactory
cytology were referred to colposcopy in some programmes,
while cytology was repeated on a new sample in others.
Analysis
We present the set of the indicators routinely used to
evaluate the performance of screening programmes,
stratified by country of birth (Italy vs. other countries).
For two programmes, migrants were further stratified in
women from low/medium income and from high in-
come countries. The indicators included participation
(crude and adjusted – i.e., accounting for the undeliv-
ered mails), HPV positivity, cytology triage results, recall
rate to colposcopy, compliance with colposcopy, detec-
tion rate for cervical intraepithelial neoplasia grade 2
(CIN2), CIN grade 3 (including Adenocarcinoma in situ,
CIN3), and for cancer at baseline (i.e., not including
one-year follow up for HPV+ cytology- women). Except
for participation and compliance to colposcopy, all
indicators were age-standardised using the Italy-born
screened women as standard population. For participa-
tion, cytology results, and detection rate, we calculated
age-adjusted relative risks (age-adj RR) with 95% confi-
dence intervals (95% CI).Table 1 Characteristics of the participating centres: target po








Torino 35-64 41,440 18.1
Alta Padovana 25-64 22,826 15.4
Padova 25-64 15,459 15.4
Este 25-64 31,963 8.9
Rovigo 25-64 15,534 11.4
Adria 25-64 7,464 8.5
Reggio Emilia 35-64 17,048 18.3
Valcamonica 25-64 11,095 9.5Results
Seven of the 19 pilot projects active in Italy in 2012 par-
ticipated in the survey. The duration of the study period
ranged from one to three years; the survey was restricted
to screening results of women invited between 1 January
2009 and 31 December 2011. Overall, the pilot pro-
grammes invited 162,829 women, of whom 22,814 were
immigrant (Table 1).
In the programmes that distinguished women from
low/medium income countries vs. those from high in-
come countries, the latter accounted for a small propor-
tion of all the migrants (9.4%).
Women born abroad invited for screening were on aver-
age younger than Italians (mean age 43.3 vs. 46.7 years,
respectively). The participation was lower in born abroad
than in Italy-born women (43.6% vs. 52.2%), though the
difference was noticeable only in women aged ≥ 40 years
(Figure 1).
The overall participation rate in women from high-
income countries was lower than the average of women
born abroad (44% vs 47% and 61% vs 65% in Turin and
Reggio Emilia, respectively).
The overall age-adjusted HPV positivity rate was higher
in born abroad than in Italy-born women (age-adj RR
1.18, 95% CI 1.13-1.22), with a different shape by age
(Figure 2): the curve for Italians decreased sharply with
age, while the migrants showed a modest decrease
between ages 25 and 40 and a second peak after meno-
pause. As a result, young women born abroad had
a lower HPV prevalence than did young Italy-born
women. Women born in high income countries showed
a prevalence curve very similar to Italians.
Among HPV+ women, the prevalence of cyto + was
similar in migrants and Italians, resulting in higher refer-
ral to both colposcopy and one-year follow up for mi-
grants. Women born abroad had a higher proportion of
high-grade cytology (H-SIL, ASC-H, and cancer) thanpulation, proportion of foreigners, study period, and
Period Information about immigration status
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Figure 1 Participation in HPV-based cervical cancer screening by age and place of birth. A. Torino and Reggio Emilia, target age 35–64. B. Veneto
and Valcamonica, target age 25–64.
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0.0001) (Table 2).
Compliance to colposcopy referral was high in both groups
(91.7% and 93.5% for immigrants and Italians, respectively).
The detection rate of CIN2+ was higher for women
born abroad than for Italians (8.2‰ vs. 4.7‰). The dif-
ference was entirely due to an excess of CIN3+ (age-adj
RR 2.29, 95% CI 1.90-2.75), while a negligible difference
was observed for CIN2 (age-adj RR 1.07, 95% CI 0.88-
1.31) (Table 2). The detection rate was different also by
age: the risk was lower for women born abroad than for
Italians below age 30, while at older ages the risk de-
creased in Italians but remained stable in women born
abroad, resulting in an excess of CIN2+ in the latter in
women older than 40 years 40 (Figure 3). Women from
high income countries showed an overall age-adjusted
detection rate lower than that of Italians.
Five of the 15 cancers identified was found in women
born abroad, who accounted for only 12% of the
screened population. In fact, the cancer detection rate
was about four times higher in women born abroad than





























Figure 2 Proportion of women HPV positive (Hybrid Capture II, high-risk tyDiscussion
This is the first study reporting the results of several
population-based screening programmes that adopted
HPV DNA as primary screening stratified for migrant
and native population in an industrialized country. In
Italy, HPV DNA-based screening was implemented quite
early: the first pilot programme started in 2007, [32] and
in January 2013 the Ministry of Health adopted the HTA
Italian report, [47] thus allowing the Public Health
Service to introduce HPV DNA as primary screening.
Participation
Several of the HPV DNA test pilot programmes reported a
slightly higher participation than that of Pap test-based pro-
grammes [32-36]. However, this increase is unlikely to reduce
the gap in participation between Italians and immigrants. In
fact, our survey detected a difference in participation between
Italians and immigrants, both from high income and from
low/medium income countries, similar or even higher than
that observed in Pap test-based programmes [48].
Nevertheless, population-based screening programmes
are effective interventions in reducing inequality in the4 45-49 50-54 55-59 60-64
e class
oad Italy-born
pes) by age and place of birth.
Table 2 Main data and principal performance indicators of seven Italian pilot programmes adopting HPV as primary
screening test followed by cytology triage, by country of birth
Relative risk immigrants vs. Italians
Italy-born Born abroad Crude RR 95% CI Age adjusted RR 95% CI
N (%)* N (%)*
Invited Population (N) 140,015 22,814
Undelivered letters 1,305 0.9 1196 5.2
Participants 73,023 52.2 9941 43.6 0.84 (0.82-0.85)
Participation excluding undelivered letters (%) 52.6 46.0 0.87 (0.86-0.89)
HPV tests performed 72,176 9680
HPV positive 4,421 6.1 751 7.8 1.27 (1.18-1.36) 1.18 (1.13-1.22)
cytological triage*
Negative 1,925 48.4 326 49.2
Inadequate 180 4.5 24 3.6
ASC-US 444 11.2 66 10.0
AGC 17 0.4 5 0.8
L-SIL 1,173 29.5 174 26.3
ASC-H 74 1.9 22 3.3
H-SIL 158 4.0 42 6.3
Cancer 3 0.1 3 0.5
Total ASC-US+ (% of HPV positive) 1,869 47.0 312 47.1 0.98 (0.87-1.07) 0.95 (0.90-0.99)
Referred to colposcopy 1,968 2.7 324 3.3 1.23 (1.09-1.38) 1.22 (1.09-1.37)
Compliance to colposcopy 1,840 93.5 297 91.7 0.98 (0.95-1.02)
Detection rate for CIN3+ (‰ screened women) 163 2.3 50 5.2 2.29 (1.67-3.14) 2.29 (1.90-2.75)
Detection rate for CIN2+ (‰ screened women) 342 4.7 79 8.2 1.72 (1.35-2.20) 1.65 (1.45-1.89)
CIN2 179 52.3 29 36.7
CIN3 + adeno in situ 153 44.7 45 56.7
Invasive Cancer 10 5.6 5 17.2 3.73 (1.27-10.90) 3.9 (1.33-11.41)
Positive predictive value of colposcopy referral 18.6 26.6 1.43 (1.16-1.77) 1.38 (1.12-1.71)































Figure 3 Detection rate of CIN2+ by age and place of birth.
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difference in Pap test coverage between Italians and im-
migrants is smaller in the regions where well-organized
screening programmes are present, compared to those
regions where screening programmes cannot regularly
invite all the population and the access to Pap test is
mainly spontaneous [52]. This effect occurs even when
the participation is slightly lower for immigrants than
for Italians, but given the much lower uptake of oppor-
tunistic screening by immigrants, organised programmes
contribute to reducing inequality, which should be the
case with HPV DNA-based screening as well.
Prevalence of HPV infections and high-grade lesions
The prevalence of HPV infection was higher in immi-
grants than in Italians. Also, the curve of prevalence by
age was different in the two groups: the results in Italian
women confirmed the prevalence curve already observed
in previous population-based studies [53-55], with a
constant decline with age, which was steep until age 40
and flatter from ages 45 to 65. The prevalence in immi-
grants, instead, decreased slightly from ages 25 to 35
and then remained almost flat.
The curve in immigrants is similar to that of many
low/medium income countries such as sub-Saharan Africa,
central Asia, and Latin America [56], but not to some of
other countries most represented among immigrants
resident in Italy (e.g. Mediterranean Africa, the Middle
East, and Indian sub-continent [17,56]. The foreign
population in Italy is extremely heterogeneous in terms
of country of origin: the first 5 countries (Romania,
Albania, Morocco, China, and the Ukraine) account for
only 50% of the foreign population [24]. Furthermore,
the different populations are not evenly distributed by
age [24]. Thus, the overall prevalence curve probably
reflects the distribution by age of some communities
with a very high prevalence in their countries of origin,
such as sub-Saharan Africa and Eastern Europe, and of
other communities with a low HPV prevalence, such as
Mediterranean Africa and Indian sub-continent. The
latter immigrants are younger, while women from
Eastern Europe, an area with a very high prevalence,
tend to be older.
It is worth noting that the overall proportion of cyto +
among HPV+ women is very similar in Italians and im-
migrants, while the proportion of high-grade lesions is
higher in immigrants. A higher proportion of women
with high-grade cytology is consistent with a higher de-
tection rate of CIN2+ and particularly of CIN3 in immi-
grants than in Italians. A ratio between high-grade and
low-grade lesions in favour of high grade is probably
linked to a lower uptake of screening among immigrants
in the preceding years, both in their countries of origin
and in Italy. This means that long-lasting and moresevere lesions are detected. Indeed, a higher detection
rate may be the consequence of both higher HPV preva-
lence and lower screening uptake in the preceding years.
All of the observed differences between immigrants and
Italians suggest that the immigrant populations maintain
the prevalence of their countries of origin for several
years, particularly when migration is a relatively recent
phenomenon (as it is in Italy). Many other studies have
also observed this phenomenon when looking at HPV
prevalence [16,57], cytological abnormalities [18,19,48],
and pre-cancer or cancer risk [5,7-15].
Limits and strengths
The country of birth, which we used as a proxy of the
migration status, could misclassify women, thereby
including many Italian women among the migrants.
Nevertheless, even citizenship, unanimously considered
a better proxy of migrant status in women aged 25–64,
can misclassify a significant number of women who are
married to Italians but who migrated to Italy relatively
recently. Another Italian study compared cervical cancer
screening indicators obtained using the country of birth
or citizenship and found only minor differences [48].
We decided to use the country of birth because this
information was more uniformly collected by the
programmes and it was probably the most reliable.
Furthermore, only few programmes could distinguish
women from low/medium income from those from
high-income countries. All the analyses confirmed that,
in Italy now, calculating the indicators for all the for-
eigners provides figures that substantially depict the
health status of immigrants.
Differences between native and immigrant women
tend to decrease with time after the arrival in the host
country [15]. In the case of cervical cancer risk, it would
be interesting to observe the time needed to reduce the
gap in screening participation and in HPV prevalence.
Unfortunately we do not have information on the length
of stay in Italy.
On the other hand, the characteristics of immigrants
from high-income countries were substantially com-
parable to those of Italians, with the exception of
participation.
Another limit of this study is that we could not iden-
tify the exact country of origin. HPV prevalence differs
in different areas and it would be important to distin-
guish between countries with high vs. low prevalence, in
order to determine whether the prevalence of commu-
nities resident in Italy reflects the country of origin.
Analyses by specific communities are necessary to better
understand the epidemiology of HPV and cervical cancer
in immigrants and to target public health interventions.
Furthermore, we could not distinguish between women
at their first screening round and those who had already
Campari et al. Infectious Agents and Cancer  (2015) 10:14 Page 7 of 9had a previous Pap test. On the other hand, it must be
noted that almost all the women included in this survey
were at their first HPV screening test.
Finally, screening programmes actively invite only
women that are resident, or at least registered, in their
catchment area, while irregular migrants and asylum
seekers, who are surely more vulnerable than are regular
residents, can only access screening spontaneously.
Therefore we have information only on regular immi-
grants, registered as such. While citizens from outside
of the European Union (i.e. all the regular immigrants
but not tourists or those with a short-term or a study
visa) must be registered residents, the same is not true
for European Union citizens. However, since residents
can obtain tax reductions, reduced fees for electricity,
gas, water supplies, and so on, not being resident has
many disadvantages. Thus, persons staying for a long
time usually are registered as resident.Conclusions
Immigrant women have a higher prevalence of HPV, a
worse ratio of high-grade vs. low-grade lesions, and
consequently a higher risk of cervical pre-cancer and
cancer than do Italians. The prevalence of HPV seems
to reflect that of their countries of origin. HPV DNA-
based programmes are not likely to reduce the gap in
participation in screening programmes between immi-
grants and Italians.
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